Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-IgG) (BSSG-386)

Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-PD1 antibody variable domain are respectively connected to the N terminus of the anti-CD3 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & PD1

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes.

Target 2

PD1

Gene ID

5133

UniProt ID

Q15116

Alternative Names

PDCD1; programmed cell death 1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; programmed cell death protein 1; protein PD-1; systemic lupus erythematosus susceptibility 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-IgG) (BSSG-386). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-IgG) (CAT#: BSSG-386)

Specifications

Targets

Customer Reviews and Q&As